Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Amine Belhabri, MD, Liliana Vila, MD, Mael Heiblig, Stephane Morisset, BioStat, Emmanuelle Nicolas-Virelizier, MD, Clémence Santana, MD, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Anne-Sophie Michallet, MD PhD, Philippe Rey, MD, Yann Guillermin, MD, Souad Assad, MD, Laure Lebras, MD, Mauricette Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142956

Published: 2020

Journal Articles

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

Adriana Plesa, Christophe Roumier, PharmD, Florent Dumezy, PharmD, Delphine Manzoni, PharmD, Pierre Sujobert, MD PhD, Sandrine Hayette, Isabelle Tigaud, MD, Claude Preudhomme, Karine Celli-Lebras, CRA, Yves Bertrand, MD, Herve Dombret, Xavier Thomas, MD, Meyling Cheok, BSPharm, PhD

Blood (2018) 132 (Supplement 1): 4009.

https://doi.org/10.1182/blood-2018-99-119857

Published: 2018

Journal Articles

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Franck-Emmanuel Nicolini, MD PhD, Stéphanie Désilets, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Vila, Stephane Morisset, Stat, Mohamad Sobh, PharmD, Mauricette Michallet, MD PhD, Valerie Dubois, MD

Blood (2018) 132 (Supplement 1): 5436.

https://doi.org/10.1182/blood-2018-99-117733

Published: 2018

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/ IL3-IGH Rearrangement and Eosinophilia: A Peculiar IGH BCP-ALL

Blood (2017) 130 (Supplement 1): 2572.

https://doi.org/10.1182/blood.V130.Suppl_1.2572.2572

Published: 2017

Journal Articles

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Gaelle Fossard, MD, Vincent Alcazer, MD, Marie Balsat, MD, Helene Labussiere-Wallet, MD, Stephane Morisset, Stat, Mohamad Sobh, Isabelle Tigaud, MD, Pierre Sujobert, MD PhD, Mauricette Michallet, MD PhD, Franck Emmanuel Nicolini, MD PhD

Blood (2017) 130 (Supplement 1): 2900.

https://doi.org/10.1182/blood.V130.Suppl_1.2900.2900

Published: 2017

Journal Articles

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Franck E. Nicolini, MD PhD, Marie Balsat, MD, Maud Lekieffre, MD, Vincent Alcazer, MD, Hélène Labussière-wallet, MD, Sarah Huet, PharmD, PhD, Sandrine Hayette, Stéphanie Dulucq, PharmD, PhD, Stéphane Morisset, Stat, Jeremy Ruby, CRA, Isabelle Tigaud, MD, Marie-Pierre Fort, CRA, Mael Heiblig, MD, Rémi Chapelon, CRA, Madeleine Etienne, CRA, Mohamad Sobh, PharmD, Francois-Xavier Mahon, MD PhD Professor, Mauricette Michallet, MD PhD, Gabriel Etienne, MD PhD

Blood (2015) 126 (23): 2774.

https://doi.org/10.1182/blood.V126.23.2774.2774

Published: 2015

Journal Articles

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Blood (2014) 124 (21): 2324.

https://doi.org/10.1182/blood.V124.21.2324.2324

Published: 2014

Journal Articles

Value of Cytogenetic Abnormalities in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Treated in the Pediatric-Inspired Trials from the Group for Research on Adult ALL (GRAALL)

Blood (2014) 124 (21): 492.

https://doi.org/10.1182/blood.V124.21.492.492

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Jeremy Monfray, CRA, Hélène Labussière-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 2542.

https://doi.org/10.1182/blood.V124.21.2542.2542

Published: 2014

Journal Articles

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Blood (2014) 124 (21): 68.

https://doi.org/10.1182/blood.V124.21.68.68

Published: 2014

Journal Articles

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3892.

https://doi.org/10.1182/blood.V124.21.3892.3892

Published: 2014

Journal Articles

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Mohamed Elhamri, PhD, Jeremy Monfray, CRA, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Adriana Plesa, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3691.

https://doi.org/10.1182/blood.V124.21.3691.3691

Published: 2014

Journal Articles

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Helene Labussiere, MD, Lila Gilis, MD, Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Sophie Ducastelle, MD, Xavier Thomas, MD

Blood (2013) 122 (21): 2721.

https://doi.org/10.1182/blood.V122.21.2721.2721

Published: 2013

Journal Articles

Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed El Hamri, PhD, Lila Gilis, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD, PhD, Xavier Thomas, MD

Blood (2013) 122 (21): 2162.

https://doi.org/10.1182/blood.V122.21.2162.2162

Published: 2013

Journal Articles

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Florence Beckerich, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Adriana Plesa, MD, Valerie Dubois, MD, Isabelle Mollet, Helene Labussiere, MD, Lila Gilis, MD, Sophie Ducastelle, MD, Oriane Le Borgne, CRA, Jeremy Monfray, CRA, Fiorenza Barraco, MD, Isabelle Tigaud, MD, Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2013) 122 (21): 4639.

https://doi.org/10.1182/blood.V122.21.4639.4639

Published: 2013

Journal Articles

Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot Study

Blood (2012) 120 (21): 4549.

https://doi.org/10.1182/blood.V120.21.4549.4549

Published: 2012

Journal Articles

CML Patients Show Sperm Alterations At Diagnosis That Are Not Improved On Tyrosine Kinase Inhibitor Treatment

Franck E. Nicolini, MD, PhD, Françoise Huguet, Hélène Labussière-Wallet, MD, Yann Guillermin, MD, Madeleine Etienne, CRA, Marie-Pierre Fort, CRA, Isabelle Tigaud, MD, Sandrine Hayette, Stephane Morisset, Stat., Mohamad Sobh, Pharm.M., Fiorenza Barraco, MD, Mauricette Michallet, MD, PhD, Myriam Daudin, MD, Volcy Soula, MD, Sandrine Giscard d'Estaing, MD, Gabriel Etienne, MD, PhD

Blood (2012) 120 (21): 1669.

https://doi.org/10.1182/blood.V120.21.1669.1669

Published: 2012

Journal Articles

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Gabriel Etienne, MD, PHD, Nicolini E Nicolini, MD, PhD, Stéphanie Dulucq, Anna Schmitt, Sandrine Hayette, Éric Lippert, MD, PhD, Isabelle Tigaud, MD, Stephane Morisset, Stat., Caroline Bureau, Didier Adiko, Gerald Marit, MD, Josy Reiffers, MD, Francois-Xavier Mahon, MD, PhD

Blood (2012) 120 (21): 3754.

https://doi.org/10.1182/blood.V120.21.3754.3754

Published: 2012

Journal Articles

Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center Cohort

Hélène Labussière-Wallet, MD, Yann Guillermin, MD, Madeleine Etienne, CRA, Anne-Claire Barale, Caroline Serrier, MD, Isabelle Tigaud, MD, Sandrine Hayette, Oriane Le Borgne, CRA, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Fiorenza Barraco, MD, Mauricette Michallet, MD, PhD, Franck E. Nicolini, MD, PhD

Blood (2012) 120 (21): 3756.

https://doi.org/10.1182/blood.V120.21.3756.3756

Published: 2012

NARROW

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/ IL3-IGH Rearrangement and Eosinophilia: A Peculiar IGH BCP-ALL

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Value of Cytogenetic Abnormalities in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Treated in the Pediatric-Inspired Trials from the Group for Research on Adult ALL (GRAALL)

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot Study

CML Patients Show Sperm Alterations At Diagnosis That Are Not Improved On Tyrosine Kinase Inhibitor Treatment

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only